Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC boosted its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 19.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 443,312 shares of the company’s stock after acquiring an additional 70,714 shares during the period. Geode Capital Management LLC owned 1.03% of Kyverna Therapeutics worth $2,168,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC acquired a new stake in Kyverna Therapeutics in the 3rd quarter valued at about $33,000. Creative Planning acquired a new stake in shares of Kyverna Therapeutics during the 3rd quarter worth about $54,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Kyverna Therapeutics during the 3rd quarter worth about $97,000. Federated Hermes Inc. acquired a new stake in shares of Kyverna Therapeutics during the 2nd quarter worth about $120,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Kyverna Therapeutics by 2,166.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company’s stock worth $133,000 after purchasing an additional 25,997 shares during the last quarter. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Price Performance

KYTX opened at $3.86 on Wednesday. The company’s 50 day simple moving average is $4.62 and its 200 day simple moving average is $6.24. Kyverna Therapeutics, Inc. has a 1 year low of $3.54 and a 1 year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.01. The company had revenue of $0.01 million during the quarter. As a group, sell-side analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. UBS Group assumed coverage on shares of Kyverna Therapeutics in a research note on Thursday, October 10th. They set a “buy” rating and a $13.00 price target on the stock. Wells Fargo & Company decreased their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, November 15th. HC Wainwright decreased their price target on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. RODMAN&RENSHAW raised shares of Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 9th. Finally, Rodman & Renshaw assumed coverage on shares of Kyverna Therapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $25.71.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.